‘Leukodystrophy-like’ phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease

Developmental Medicine and Child Neurology

Volumn 60, Issue 4, 2018, Pages 417-423

  Hacohen, Yael ^a,b   Rossor, Thomas ^c   Mankad, Kshitij ^b   Chong, Wk ‘Kling’ ^b   Lux, Andrew ^d   Wassmer, Evangeline ^e   Lim, Ming ^c   Barkhof, Frederik ^a,f,g   Ciccarelli, Olga ^a,g   Hemingway, Cheryl ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^e BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; STEROID; AUTOANTIBODY;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ARTICLE; ATAXIA; BRAIN DISEASE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DISABILITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LEUKODYSTROPHY; MALE; MULTICENTER STUDY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY ASSOCIATED DISEASE; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PHENOTYPE; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; SEIZURE; STEROID THERAPY; TREATMENT OUTCOME; WHITE MATTER LESION; AGE; BLOOD; BRAIN; CLINICAL TRIAL; DIAGNOSTIC IMAGING; IMMUNOLOGY; IRELAND; PATHOPHYSIOLOGY; SPINAL CORD; UNITED KINGDOM;

AGE FACTORS; AUTOANTIBODIES; BRAIN; CHILD; DISABILITY EVALUATION; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; FEMALE; HUMANS; IRELAND; MAGNETIC RESONANCE IMAGING; MALE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PHENOTYPE; RETROSPECTIVE STUDIES; SPINAL CORD; UNITED KINGDOM;

EID: 85039719054     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.13649     Document Type: Article

References (22)

1. Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology 2017; 18: 269–78.
2. Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017; 89: 900–8.
3. Hacohen Y, Absoud M, Deiva K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2015; 2: e81.
4. Ketelslegers IA, Van Pelt DE, Bryde S, et al. Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler 2015; 21: 1513–20.
5. Lechner C, Baumann M, Hennes EM, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry 2016; 87: 897–905.
6. Baumann M, Hennes EM, Schanda K, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler 2016; 22: 1821–9.
7. Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72: 750–9.
8. Harris MO, Walsh LE, Hattab EM, Golomb MR. Is it ADEM, POLG, or both? Arch Neurol 2010; 67: 493–6.
9. Singh RR, Livingston J, Lim M, Berry IR, Siddiqui A. An unusual neuroimaging finding and response to immunotherapy in a child with genetically confirmed vanishing white matter disease. Eur J Paediatr Neurol 2017; 21: 410–3.
10. Reindl M, Jarius S, Rostasy K, Berger T. Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol 2017; 30: 295–301.
11. Wolf NI, Toro C, Kister I, et al. DARS-associated leukoencephalopathy can mimic a steroid-responsive neuroinflammatory disorder. Neurology 2015; 84: 226–30.
12. Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, et al. Clinical and genetic characterization of leukoencephalopathies in adults. Brain 2017; 140: 1204–11.
13. Wen X, Fuhrman S, Michaels GS, et al. Large-scale temporal gene expression mapping of central nervous system development. Proc Natl Acad Sci USA 1998; 95: 334–9.
14. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J Neurochem 1989; 52: 296–304.
15. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 1999; 72: 1–9.
16. Nave KA. Myelination and support of axonal integrity by glia. Nature 2010; 468: 244–52.
17. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016; 13: 279.
18. Sepúlveda M, Armangue T, Martinez-Hernandez E, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol 2016; 263: 1349–60.
19. Marignier R, Cobo Calvo A, Vukusic S. Neuromyelitis optica and neuromyelitis optica spectrum disorders. Curr Opin Neurol 2017; 30: 208–15.
20. Spadaro M, Gerdes LA, Krumbholz M, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016; 3: e257.
21. Longoni G, Brown RA, MomayyezSiahkal P, et al. White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. Brain 2017; 140: 1300–15.
22. Aubert-Broche B, Weier K, Longoni G, et al. Monophasic demyelination reduces brain growth in children. Neurology 2017; 88: 1744–50.